Comparison of coenzyme Q10 or fish oil for prevention of intermittent hypoxia-induced oxidative injury in neonatal rat lungs

Christina D’Agrosa¹, Charles L. Cai¹, Faisal Siddiqui¹, Karen Deslouches¹, Stephen Wadowski¹, Jacob V. Aranda¹,²,³ and Kay D. Beharry¹,²,³*

Abstract

Background: Neonatal intermittent hypoxia (IH) results in oxidative distress in preterm infants with immature antioxidant systems, contributing to lung injury. Coenzyme Q10 (CoQ10) and fish oil protect against oxidative injury. We tested the hypothesis that CoQ10 is more effective than fish oil for prevention of IH-induced lung injury in neonatal rats.

Methods: Newborn rats were exposed to two clinically relevant IH paradigms at birth (P0): (1) 50% O₂ with brief hypoxia (12% O₂); or (2) room air (RA) with brief hypoxia (12% O₂), until P14 during which they were supplemented with daily oral CoQ10, fish oil, or olive oil from P0 to P14. Pups were studied at P14 or placed in RA until P21 with no further treatment. Lungs were assessed for histopathology and morphometry; biomarkers of oxidative stress and lipid peroxidation; and antioxidants.

Results: Of the two neonatal IH paradigms 21%/12% O₂ IH resulted in the most severe outcomes, evidenced by histopathology and morphometry. CoQ10 was effective for preserving lung architecture and reduction of IH-induced oxidative stress biomarkers. In contrast, fish oil resulted in significant adverse outcomes including oversimplified alveoli, hemorrhage, reduced secondary crest formation and thickened septae. This was associated with elevated oxidants and antioxidants activities.

Conclusions: Data suggest that higher FiO₂ may be needed between IH episodes to curtail the damaging effects of IH, and to provide the lungs with necessary respite. The negative outcomes with fish oil supplementation suggest oxidative stress-induced lipid peroxidation.

Keywords: Coenzyme Q10, Fish oil, Intermittent hypoxia, Lung injury, Oxidative stress

Introduction

Extremely low gestational age neonates (ELGANs), born at < 28 weeks gestation often receive supplemental oxygen for respiratory support, with or without mechanical ventilation, during which they experience frequent, brief arterial oxygen desaturations, or apneas, which is associated with bradycardia and intermittent hypoxia (IH). In particular, ELGANs (22–23 weeks gestation) begin ventilation at the canalicular–saccular stage of lung development, well before alveolar differentiation, and surfactant production [1]. Studies show that the duration of IH shorten but increase in severity during the first month of life, and the majority of IH occurs in clusters [2]. We have shown that clustered IH events are more damaging
than dispersed IH events in neonatal rats [3]. Exposure of immature lungs to supraphysiological oxygen, combined with surfactant deficiency and poor nutrition result in poor alveolar development and microvascular maturation.

Fluctuations in oxygenation is a risk factor for long-term respiratory dysfunction, such as bronchopulmonary dysplasia [4, 5], a form of chronic lung disease (CLD) of prematurity [6, 7]. Hallmarks of the disease include vascular changes, infiltration with inflammatory cells, and alternating areas of alveolar over-inflation and atelectasis with pulmonary fibrosis [8]. Recent studies show that oxygen toxicity/hyperoxia and oxidative stress plays a significant role in the development of BPD/CLD [9]. Oxidative stress occurs when antioxidant defense mechanisms are insufficient to cope with reactive oxygen species (ROS) production, either through increased production of ROS or through insufficient presence of antioxidants. ELGANS are deficient in antioxidants which generally increase with advancing gestation, rendering them susceptible to oxidative stress and related diseases [10, 11]. Previously, studies have demonstrated an association between oxidative stress and BPD [12–14].

Coenzyme Q10 (CoQ10) is a powerful antioxidant involved in oxidative phosphorylation and is an essential part of the cellular machinery used to produce adenosine triphosphate (ATP). CoQ10 acts as a primary scavenger of free radicals, and is synthesized in-vivo [15]. Lipid emulsions high in omega 3 polyunsaturated fatty acids, such as fish oil, are widely used to improve growth and neurodevelopment in ELGANS. Fish oil supplementation has been shown to reduce oxidative stress in ELGANS [16].

Neonatal intermittent hypoxia (IH) profiles

Episodes of re-oxygenation following an IH event may occur in normoxia or hyperoxia. The two IH paradigms were: (1) exposure to 50% O₂ with brief hypoxia (50%/12% O₂ IH); or (2) exposure to normoxia with brief hypoxia (21%/12% O₂ IH), as previously described [18]. Briefly, the IH profiles consisted of: (1) an initial exposure of hyperoxia (50% O₂) for 30 min followed by three brief, 1-min, clustered hypoxic events (12% O₂), with a 10-min re-oxygenation in 50% O₂ between each hypoxic event. Recovery from IH occurred in 50% O₂ following each clustered IH event for 2.5 h for a total of 8 clustering IH episodes per day for 14 days; or (2) an initial exposure of normoxia (21% O₂) for 30 min followed by three brief, 1-min, clustered hypoxic events (12% O₂), with a 10-min re-oxygenation in 21% O₂ between each hypoxic event. Recovery occurred in normoxia following each clustered IH event for 2.5 h for a total of 8 clustering IH episodes per day for 14 days. These IH profiles are clinically relevant to those infants who experience IH with recovery in either hyperoxia or RA between episodes.

Experimental design

Within 2–4 h of birth, newborn rat pups delivering on the same day were pooled and randomly assigned to expanded litters of 18 pups/litter (nine males and nine females) for each experimental group (Additional file 1: Figure S1), as previously described [18–21]. Equal numbers for each gender in each group normalized gender differences. Expanded litter sizes in each group were implemented to simulate poor nutrition and growth experienced by ELGANS who are at the highest risk for oxidative lung injury. This is important to determine which treatment was more efficacious. Animals were exposed to neonatal IH from P0 to P14, or allowed to recover in room air (RA) until P21 with no further treatment. RA littermates, raised in atmospheric oxygen from P0 to P14 or P0 to P21, were similarly supplemented. We exposed rats to neonatal IH for 14 days because, similar to ELGANS who require oxygen therapy and who experience frequent IH episodes, rat lungs at birth are exclusively in the early saccular stage and bulk alveolarization occurs between P4–P13 [22, 23], and microvasculature is still immature. Animals were allowed to recover in room air (RA) for 1 week (P14) to determine reperfusion injury. At P21, bulk alveolarization is almost complete.

Materials and methods

Animals

Certified infection-free, timed-pregnant Sprague Dawley rats were purchased from Charles River Laboratories (Wilmington, MA) at 18 days gestation. The animals were housed in an animal facility with a 12-h-day/12-h-night cycle and provided standard laboratory diet and water ad libitum until delivery of their pups.

Treatment

From P0–P14, pups (n = 18 pups per treatment group) were administered daily oral doses of: (1) CoQ10...
(0.35 mg in 50 µL extra virgin olive oil) purchased from Sigma Aldrich (St. Louis, MO USA); (2) 50 µL fish oil containing 35 mg total n-3 PUFAs (22 mg eicosapentaenoic acid, EPA and 13 mg docosahexaenoic acid, DHA); or (3) 50 µL extra virgin olive oil. Treatments were administered using an orogastric syringe. The doses of CoQ10 and fish oil were based on our previous data [20, 21].

Sample collection and processing
Pups were euthanized at P14 or allowed to recover from neonatal IH in RA from P14 to P21. Total body weight (grams) and linear growth (crown to rump length, cm) were recorded at P0, P14, and P21 to determine percentage change and weight accretion from birth. Weight accretion evidenced by percentage changes in body weight and linear growth were calculated as weight or length at the end of the experiment (P14 or P21) minus weight or length at birth (P0) divided by the weight or length at birth × 100. Percentage change in body weight was used to standardize differences in birth weight. Whole lungs were excised and weighed to determine lung/body weight ratios. Lung to body weight ratios appear to be a more important and accurate representation of the effects of the experimental compounds on organs [24]. Biopsies were collected, rinsed in ice-cold phosphate buffered saline (PBS, pH 7.4) on ice and placed in Lysing Matrix D 2.0 mL sterile tubes containing ceramic beads (MP Biomedicals, Santa Ana, CA, USA) for assay of oxidants and antioxidants.

Lungs histology and morphometry
For histopathology and immunofluorescence (IF) staining, whole lungs (n = 6/experimental group) were infused in-situ with 10% neutral-buffered formalin (NBF), and fixed in 10% NBF for H&E staining. Unstained sections were used for IF staining. Lungs fixed in 10% NBF were processed, embedded, sectioned, and stained by the State University of New York (SUNY) Downstate Medical Center Pathology Department using standard laboratory techniques. Images were captured at 20× magnification (scale bar = 50 µm) using an Olympus BX53 microscope, DP72 digital camera, and CellSens imaging software (Olympus, Center Valley, PA), attached to a Dell Precision T3500 computer (Dell, Round Rock, TX). Morphometric analyses included total alveolar space (µM²); number of secondary crests; and width of the alveolar septae (µM) [25]. Ten sections were analyzed for each group. Measurements were made using the count and measure tool of the Olympus CellSens imaging software. Unstained sections were used for IF staining of SOD-1, SOD-2, SOD-3, and catalase.

Assay of oxidants
Levels of 8-iso-prostaglandin F₂α (8-isoPGF₂α), hydrogen peroxide (H₂O₂), and malondialdehyde (MDA) were determined in the lung homogenates using commercially available kits purchased from Enzo Life Sciences (Farmingdale, NY, USA), Cayman Chemical Co. (Ann Arbor, MI, USA), and Millipore-Sigma (St. Louis, MO, USA), respectively. All samples were processed and assayed according to the manufacturer’s protocol. A total of 6 samples per experimental group were analyzed. All data were standardized using total cellular protein levels.

Assay of antioxidants
Levels of SOD, catalase and total GSH, and total antioxidant capacity in the lung homogenates were determined using commercially available activity assay kits purchased from Cayman Chemical (Ann Arbor, MI, USA) and Millipore-Sigma (St. Louis, MO, USA), respectively. A total of 6 samples per experimental group were analyzed. Samples were processed and assayed according to the manufacturer’s protocol and standardized using total cellular protein levels.

Total cellular protein levels
On the day of assays an aliquot (10 µL) of the lung homogenates was utilized for total cellular protein levels using the Bradford method (Bio-Rad, Hercules, CA USA) with bovine serum albumin as a standard.

Immunofluorescence
Unstained lung cross-sections from 6 animals per experimental group were de-paraffinized with xylene and alcohol prior to unmasking of antigens. There were two sections per slide for each of the 6 animals per experimental group. Sections were washed several times in PBS containing triton X-100 (PBS-T) and incubated in blocking solution (5% goat serum) for 1 h. The blocking serum was removed and primary antibodies for SOD-1, SOD-2, SOD-3, and catalase (Santa Cruz Biotechnology, Dallas, TX, USA) were added, prior to incubation overnight. Sections were incubated with Alexa Fluor fluorescent secondary antibodies (ThermoFisher Sci/Life Technologies, Grand Island, NY), counterstained with DAPI and images were captured at 20× magnification (scale bar = 50 µm) using an Olympus BX53 microscope, DP72 digital camera, and CellSens imaging software attached to a Dell Precision T3500 computer (Olympus America, Inc. USA). Quantitative analysis of the staining intensity was conducted using the count and measure on
ROI tool of the CellSens software (n = 12 measurements/group).

**Statistical analysis**

Differences among the RA and the two IH groups, and differences among the supplemented groups within each oxygen environment were analyzed using two-way analysis of variance (ANOVA) with Dunnett’s post-hoc tests, following the Bartlett’s test for normality. Kruskall-Wallis nonparametric test with Dunn’s multiple comparison was used for non-normally distributed data. Data were analyzed using the Statistical Package for the Social Sciences (SPSS) software, version 26.0 (SPSS Inc., Chicago, IL, USA) and are reported as mean ± standard error of the mean (SEM). A p-value of <0.05 was considered as statistically significant.

**Results**

**Weights**

Overall, exposure to both IH paradigms (control groups supplemented with olive oil) resulted in lower percentage change in body weight at P14 (50/12% O2: 225.5 ± 7.1%, p < 0.01; 21/12% O2: 191.8 ± 9.4%, p < 0.01) and remained suppressed during the recovery/reoxygenation period at P21 (50/12% O2: 319.9 ± 12.3%, p < 0.01; 21/12% O2: 327.2 ± 12.1%, p < 0.01) compared to RA at P14 (328.1 ± 7.5%) and P21 (513.0 ± 13.5%). However, the suppressive effects of IH on body weight accretion were reversed with fish oil at P21 (50/12% O2: 499.4 ± 19.3%; 21/12% O2: 484.8 ± 15.3%). Organ weight is one of the most sensitive indicators of toxicity due to treatment with an experimental compound, and weight differences between treated and control animals may still occur in the absence of any morphological changes. Mean lung weights and lung/body weight ratios are presented in Additional file 1: Table S1. In RA, both treatments resulted in lower lung weights at P21 compared to OO. In IH, only OO decreased lung weights at P21 compared to RA. Fish oil treatment in 21%/12% O2 IH increased lung weights, but decreased lung/body weight ratios at P21.

**Lung histopathology**

Representative H&E stains of lung tissue sections from rats at P14 and P21 are presented in Figs. 1 and 2, respectively (20× magnification, scale bar is 50 µm). At P14, treatment with OO in RA showed mild hemorrhage and alveoli with thickened septae and reduced secondary crest formation. CoQ10 and fish oil treatment in RA also showed mild hemorrhage, but alveoli were more mature. Treatment with OO and CoQ10 in 50%/12% O2 IH did not result in any major abnormalities, but treatment with fish oil showed immature,
simplified alveoli with reduced secondary crest formation, thickened septae, and mild hemorrhage (arrows). These histopathological changes persisted in 21%/12% O₂ IH. At P21, there were no major abnormalities seen in the RA groups, except for larger alveoli noted in the fish oil group. However, mild hemorrhage persisted in the groups exposed to both neonatal IH paradigms. Interestingly, lung damage persisted in the group treated with fish oil in 21%/12% O₂ IH evidenced by oversimplified alveoli, reduced secondary crest formation, thickened septae, and mild hemorrhage (arrows). H&E stained lung tissue sections from rats at P14 and P21 that were exposed to neonatal IH but were untreated, are presented in Additional file 2: Figure S2 (20× magnification, scale bar is 50 µm). The upper panel represents the groups exposed to 50%/12% O₂ IH, and the middle and lower panels represent the groups exposed to 21%/12% O₂ IH. Exposure to 51%/12% O₂ resulted in mild hemorrhage with reduced alveoli at P14 (arrows). At P14, while evidence of hemorrhage persisted, the alveoli were larger. In contrast, animals exposed to 21%/12% O₂ IH showed pervasive hemorrhage at P14 with simplified alveoli, loss of secondary crests, and thickened septae which persisted at P21 (arrows).

Lung morphometry
Quantitative morphometric analyses for lungs at P14 and P21 are presented in Additional file 12: Table S2, Additional file 13: Table S3, respectively. At P14, both treatment groups exposed to room air showed a decrease in septal thickness when compared to OO controls. In IH, CoQ10 supplementation decreased alveolar number, length of secondary crests, and alveolar diameter and area, but increased the number of secondary crests, compared to OO. In contrast, fish oil treatment in IH decreased all parameters, except septal thickness which was elevated in 50%/12% O₂ IH. At P21, the effects persisted particularly with fish oil treatment in 21%/12% O₂ IH.

Oxidative stress
Levels of oxidants (H₂O₂, 8-isoPGF₂α, and MDA) in the lung homogenates at P14 and P21, are presented in Fig. 3. H₂O₂ and 8-isoPGF₂α levels in the lung homogenates are presented in Fig. 4. At P14, both neonatal IH paradigms significantly increased lung H₂O₂ levels. CoQ10 effectively suppressed H₂O₂ in all oxygen environments, but fish oil was less effective and resulted in elevated H₂O₂ levels in RA. This effect persisted at P21, although a rebound elevation of H₂O₂ was seen with CoQ10.
Fig. 3  Effects of CoQ10 or fish oil supplementation during neonatal IH on the oxidants, hydrogen peroxide (H$_2$O$_2$), 8-isoprostaglandin F$_{2\alpha}$ (8-isoPGF$_{2\alpha}$), and malondialdehyde (MDA), in lung homogenates on postnatal day 14 (P14) and P21. Pups were exposed to neonatal IH from P0 to P14 during which they were supplemented with CoQ10 or fish oil. Post-IH, animals were either euthanized at P14 or placed in RA with no further supplementation for re-oxygenation/recovery until P21. RA control littersmates (white bar) remained in RA from birth to P14 or P21. The shaded bars represent groups exposed to 50%/12% O$_2$ IH, and the solid black bars represent groups exposed to 21%/12% O$_2$ IH. Data are expressed as mean ± SEM (n = 6 samples/group).

Fig. 4  Effects of fish oil or CoQ10 supplementation during neonatal IH on the antioxidants, superoxide dismutase (SOD), catalase or glutathione, in lung homogenates on postnatal day 14 (P14) and P21. Pups were exposed to neonatal IH from P0 to P14 during which they were supplemented with fish oil or COQ10. Groups are as described in Fig. 1. Data are expressed as mean ± SEM (n = 6 samples/group).
treatment in RA. A quite different effect was noted for 8-isoPGF$_{2\alpha}$, CoQ10 caused significant elevations in 8-isoPGF$_{2\alpha}$ levels in all oxygen conditions at P14 and fish oil reduced it in 50%/12% O$_2$ IH. At P21, 8-isoPGF$_{2\alpha}$ levels remained elevated in 50%/12% O$_2$ IH with all treatments, but the highest levels occurred with fish oil. In 21%/12% O$_2$ IH, 8-isoPGF$_{2\alpha}$ levels increased with both CoQ10 and fish oil. Lung MDA, representing lipid peroxidation, was elevated with olive oil in 50%/12% O$_2$ IH, and with fish oil in IH. At P21, sustained MDA increases were seen with in fish oil in all oxygen conditions.

**Antioxidants**

Levels of antioxidants and total antioxidant capacity in the lung homogenates are presented in Figs. 2, 3, 4, 5, 6. Total SOD, catalase and glutathione at P14 and P21 is presented in Fig. 4. At P14, SOD was significantly elevated with CoQ10 in RA, and OO in 50%/12% O$_2$ IH compared to OO treatment in RA. Catalase activity was induced in the OO and fish oil groups exposed to IH, but lowered with CoQ10. Total glutathione levels were higher with fish oil treatment in both IH conditions, but with OO and CoQ10 in 21%/12% O$_2$ IH only. At P21, SOD and catalase activities were elevated in response to both IH paradigms with OO and fish oil supplementation. Glutathione was increased with OO in 21%/12% O$_2$ IH group and with fish oil treatment in both IH conditions. Corresponding IF stains of SOD-1, SOD-2, SOD-3, and catalase at P14 and P21 are shown in Additional file 3: Figure S3, Additional file 4: Figure S4, Additional file 5: Figure S5, Additional file 6: Figure S6, Additional file 7: Figure S7, Additional file 8: Figure S8, Additional file 9: Figure S9, Additional file 10: Figure S10, respectively. Quantitative analyses of the IF stains for SOD isoforms in the lung sections are presented in Fig. 5. At P14, SOD-1 was elevated with all treatments compared to OO in RA, but was higher with fish oil. SOD-2 was higher with OO in both IH conditions, and with fish oil in 21%/12% O$_2$ IH. SOD-3 was increased with fish oil in all oxygen environments. At P21, the effects on SOD-2 and SOD-3 persisted with OO and fish oil. Quantitative analysis of catalase IF stains in the lung sections, and total antioxidant capacity in the lung homogenates at P14 and P21, are presented in Fig. 6. At P14, catalase increased with all treatments in 21%/12% O$_2$ IH, but the effect was substantial with fish oil. Total antioxidant capacity was higher with OO and fish oil in 21%/12% O$_2$ IH. At P21, elevations in catalase and total antioxidant capacity persisted in the fish oil group.

**Fig. 5** Quantitative analysis of SOD-1, SOD-2, and SOD-3 immunofluorescence staining intensity in the lung sections from rats at P14 and P21. Corresponding images are presented in the Additional file 2: Figure S2, Additional file 3: Figure S3, Additional file 4: Figure S4, Additional file 5: Figure S5, Additional file 6: Figure S6, Additional file 7: Figure S7). Groups are as described in Fig. 1. Data are presented as mean ± SEM (n = 12 samples/group).
Discussion

The major findings of this report are: (1) while both neonatal IH paradigms were damaging to the immature lungs, resolution with normoxia between IH episodes was more injurious than IH resolving in hyperoxia. This finding was unexpected, and is likely due to the shorter FiO2 range from 21 to 12% compared to 50% to 12%, which allowed the lungs more respite from the effects of hypoxia; (2) CoQ10 was more effective for reducing IH-induced lung injury than fish oil, and the damage was associated with significant elevations in H2O2 and MDA. Both H2O2 and MDA are indicators of lipid peroxidation. H2O2 is produced by dismutation of superoxide anion by SOD and in excess, can react with free iron to form the reactive hydroxyl radical which destroys lipids, proteins, and DNA via the Fenton–Haber–Weiss reaction [26]. MDA is formed as a product of lipid peroxidation, the reaction of oxygen with unsaturated lipids, and appears to be the most mutagenic product of lipid peroxidation [27]; and (3) reduced lung/body weight ratios in the control groups exposed to neonatal IH may be reflective of overall abnormal growth and development of the lungs which persisted during the recovery/reoxygenation period. These findings strongly imply that in the setting of neonatal IH, the use of lipids may perpetuate oxidative stress injury due to its susceptibility to oxidation. Although frequently described as having antioxidant properties, studies show that fish oil are highly prone to oxidation [28]. Therefore, combining lipids with antioxidants may improve its therapeutic efficacy and reduce the effects of ROS on lipids, and may be essential for preserving its stability and therapeutic efficacy in neonatal IH [29]. Further studies are needed to confirm this.

The two IH paradigms used in this study were designed to simulate the acute oxygen desaturations seen in ELGANs with respiratory distress syndrome. Both paradigms address the clinical question of whether resolution of an IH episode with room air or hyperoxia between episodes is more beneficial to the developing lungs. In our study, we found that lung damage worsened during recovery/reoxygenation at P21, and was in line with many studies which reported that hypoxia/reoxygenation events produce the most damaging outcomes, known as reperfusion injury, of which oxygen free radicals appear to be highly involved [30]. Comparing the two IH paradigms, it is likely that 21%/12% O2 IH model may be associated with a higher activation of hypoxia/ischemia. Reoxygenation in 21%
O2 between episodes was insufficient to counteract the effects, before the next IH insult initiated. Restitution of blood flow during reperfusion injury occurs in damaged, leaky vessels leading to hemorrhage which was noted predominantly with the 21%/12% O2 IH paradigm. On the other hand, reoxygenation in 50% O2 following neonatal IH provided a higher FiO2 that may be necessary to override the mechanisms associated with hypoxia/ischemia. Although both paradigms are detrimental to the developing lungs, increasing oxygen for resolution between episodes may reduce the severity of lung damage.

In oxidative stress, the first oxidant produced is superoxide anion. The natural defense against superoxide is its dismutation by SOD to H2O2 and oxygen. Subsequently, H2O2 is detoxified by catalase and glutathione. These antioxidants are induced or repressed to match the intensity of ROS production. Fish oil supplementation in IH caused robust production of oxidants and responsive antioxidants. This finding strongly suggests that in the setting of neonatal IH, the antioxidant benefits of fish oil may be diminished. Specifically, fish oil is consumed in the diet and absorbed via the gut, and have been implicated as a trigger for oxidative stress and inflammation in the intestine [31]. Recent studies showed that fish oil, at best, does not decrease the incidence of BPD [32, 33]. The finding of elevated antioxidants during recovery/reoxygenation in the fish oil group strongly suggest a robust response to increased ROS production. Whether increased ROS is due to fish oil peroxidation, diminished antioxidant capacity, or both remains to be determined. CoQ10 was shown to effectively suppress oxidative damage and antioxidants in the lungs exposed to both neonatal IH paradigms. CoQ10 also did not affect overall lung weight or lung to body weight ratios. More importantly, CoQ10 was associated with lower SOD and GSH which are generally induced in response to oxidative stress and may indicate a necessary mitochondrial defense [34]. In the lung SOD-3 is the predominant isof orm and has been implicated as a major player in the prevention of hypoxic lung injury and BPD [35–37]. Notably, robust elevations occurred in the fish oil groups, particularly with exposure to 21%/12% O2 IH which also manifested the most damage, and produced characteristics consistent with BPD [38]. Under normal conditions, after day 10 of life, the lung of the neonatal rat should show signs of further septation, including lengthening and thinning of old septa and development of secondary septa to form new alveoli [22]. CoQ10 supplementation was shown to improve lung architecture despite exposure to neonatal IH. However, further studies are needed to determine its safety and efficacy for use in preterm infants.

Conclusions
Lipids emulsions are widely used in neonates to improve growth, visual function, and neurodevelopmental outcomes. The efficacy of lipids for prevention of lung inflammation is controversial. Our findings show that neonatal IH induces H2O2 and MDA, further supporting lipid peroxidation. CoQ10, remains promising in the prevention of a multitude of human diseases. However, its safety and efficacy for prevention and/or treatment of oxidative stress diseases of the neonate require appropriate and extensive preclinical investigations.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12931-021-01786-w.

Additional file 1: Figure S1. Flow chart of Experimental Design. Animals were placed in neonatal intermittent hypoxia (IH) conditions from the first day of life, postnatal day 0 (P0) until P14 during which the received oral supplementation with olive oil (control), coenzyme Q10, or fish oil. At P14, pups were placed in room air conditions until P21 for reoxygenation/reperfusion, with no further supplementation. Room air littermates remained in normoxic conditions from P0 to P21 and were similarly supplemented.

Additional file 2: Figure S2. Representative H&E stained images of lungs from non-supplemented rats exposed to 50%/12% O2 intermittent hypoxia (IH) or 21%/12% O2 IH at P14 and P21. Images are 20x magnification and the scale bar is 50 µM. Arrows show hemorrhage and simplified alveoli.

Additional file 3: Figure S3. Representative image showing immunoreactivity of superoxide dismutase (SOD)-1 in the lung sections from groups supplemented with fish oil or CoQ10 during neonatal IH at P14. Images are 20x magnification and the scale bars are 50 µM.

Additional file 4: Figure S4. Representative image showing immunoreactivity of superoxide dismutase (SOD)-1 in the lung sections from groups supplemented with fish oil or CoQ10 during neonatal IH at P21. Images are 20x magnification and the scale bars are 50 µM.

Additional file 5: Figure S5. Representative image showing immunoreactivity of superoxide dismutase (SOD)-2 in the lung sections from groups supplemented with fish oil or CoQ10 during neonatal IH at P21. Images are 20x magnification and the scale bars are 50 µM.

Additional file 6: Figure S6. Representative image showing immunoreactivity of superoxide dismutase (SOD)-2 in the lung sections from groups supplemented with fish oil or CoQ10 during neonatal IH at P14. Images are 20x magnification and the scale bars are 50 µM.

Additional file 7: Figure S7. Representative image showing immunoreactivity of superoxide dismutase (SOD)-3 in the lung sections from groups supplemented with fish oil or CoQ10 during neonatal IH at P14. Images are 20x magnification and the scale bars are 50 µM.

Additional file 8: Figure S8. Representative image showing immunoreactivity of superoxide dismutase (SOD)-3 in the lung sections from groups supplemented with fish oil or CoQ10 during neonatal IH at P21. Images are 20x magnification and the scale bars are 50 µM.

Additional file 9: Figure S9. Representative image showing immunoreactivity of catalase in the lung sections from groups supplemented with fish oil or CoQ10 during neonatal IH at P14. Images are 20x magnification and the scale bars are 50 µM.
Additional file 10: Figure S10. Representative image showing immuno-reactivity of catalase in the lung sections from groups supplemented with fish oil or CoQ10 during neonatal IH at P21. Images are 20× magnification and the scale bars are 50 µM.

Additional file 11: Table S1. Lung Weights and Lung/Body Weight Ratios.

Additional file 12: Table S2. Lung Morphometric Analyses at P14.

Additional file 13: Table S3. Lung Morphometric Analyses at P21.

Authors’ contributions
All authors have made substantial contributions to the conception (CD, JVA, KDB), design of the work (CD, JVA, KDB), acquisition and analysis (CD, CLC, FS, KD, KDB), interpretation of the data (CD, JVA, KDB), original draft (CD), and review and approval of the submitted version (CD, CLC, FS, KD, SW, JVA, KDB). All authors agree to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature. All authors read and approved the final manuscript.

Funding
This work was made possible through the Eunice Kennedy Shriver National Institute of Child Health & Human Development Grant #U54HD071594 and the Alicia and Madu Rao Translational Research Foundation Grant EIN 262145011.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
All experiments were approved by the State University of New York, Downstate Medical Center Institutional Animal Care and Use Committee, Brooklyn, NY (Protocol #17-10517). Animals were cared for according to the guidelines of the United States Department of Agriculture and the Guide for the Care and Use of Laboratory Animals.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Pediatrics and Ophthalmology, Division of Neonatal-Perinatal Medicine Clinical and Translational Research Labs, State University of New York, Downstate Medical Center, 450 Clarkson Avenue, Box 49, Brooklyn, NY 11203, USA. 2 Department of Ophthalmology, State University of New York, Downstate Medical Center, Brooklyn, NY 11203, USA. 3 State University of New York Eye Institute, New York, NY, USA.

Received: 27 April 2021 Accepted: 28 June 2021 Published online: 05 July 2021

References
1. Thiebaud B, Goss KN, Laughon M, Whitsett JA, Abman SH, Steinhorn RH, Aschner JL, Davis PG, McGrath-Morrow SA, Soll RF, Jabe AH. Bronchopulmonary dysplasia. Nat Rev Dis Primers. 2019;5(1):78.
2. Di Fiore JM, Kaffash F, Loparo K, Sattar A, Schluchter M, Fogliano R, Martin RJ, Wilson CG. The relationship between patterns of intermittent hypoxia and retinopathy of prematurity in preterm infants. Pediatr Res. 2012;72:606–12.
3. Coleman RJ, Beharry KD, Brock RS, Abad-Santos P, Abad-Santos M, Modanlou HD. Effects of brief, clustered versus dispersed hypoxic episodes on systemic and ocular growth factors in a rat model of oxygen-induced retinopathy. Pediatr Res. 2008;64:50–5.
4. Dyflag AM, Mayer CA, Raffay TM, Martin RJ, Jafri A, MacFarlane PM. 2017 Long-term effects of recurrent intermittent hypoxia and hyperoxia on respiratory system mechanics in neonatal mice. Pediatr Res. 2017;81:565–71.
5. Ratner V, Kishikumo SV, Slinko SK, Lososov SA, Lososov AA, Polin RA, Ten VS. The contribution of intermittent hypoxemia to late neurologic- nal handicap in mice with hyperoxia induced lung injury. Neonatology. 2007;92:50–8.
6. Jensen EA, Schmidt B. Epidemiology of bronchopulmonary dysplasia. Birth Defects Res A Clin Mol Teratol. 2014;100(3):145–57.
7. Ibrahim J, Bhandari V. The definition of bronchopulmonary dysplasia: an evolving dilemma. Pediatr Res. 2018;84(5):586–8.
8. Hvag JP, Rehan VK. Recent advances in bronchopulmonary dysplasia: pathophysiology, prevention, and treatment. Lung. 2018;196(2):129–38.
9. Saugstad OD. Bronchopulmonary dysplasia-oxidative stress and antioxidants. Semin Neonatol. 2003;8(1):39–49.
10. Perez M, Robbins ME, Revhaug C, Saugstad OD. Oxygen radical disease in the newborn, revisited: oxidative stress and disease in the newborn period. Free Radic Biol Med. 2019;126:61–72.
11. Buss IH, Darlow BA, Winterbourn CC. Elevated protein carbonyls and lipid peroxidation products correlating with myeloperoxidase in tracheal aspirates from premature infants. Pediatr Res. 2000;47(5):640–5.
12. Capasso L, Vento G, Loddo C, Tironi C, Lavarrone F, Raimondi F, Dani C, Faino V. Oxidative stress and bronchopulmonary dysplasia: evidences from microbiomics, metabolomics, and proteomics. Front Pediatr. 2019;7:30.
13. Wang J, Dong W. Oxidative stress and bronchopulmonary dysplasia. Gene. 2018;678:177–83.
14. Perrone S, Tataranno ML, Buonocore G. Oxidative stress and bronchopulmonary dysplasia. J Clin Neonatol. 2012;1(9):109–14.
15. Garrido-Maraver J, Cordero MD, Oropesa-Avila M, Vega AF, de la Mata M, Pavon AD, Alcocer-Gomez E, Calero CP, Paz MV, Alanis M, de Lavera I, Cotan D, Sanchez-Alcazar JA. Clinical applications of coenzyme Q10. Front Biosci. 2014;19:619–33.
16. Skouroliakou M, Konstantinou D, Koutri K, Kakavelakis C, Statopoulos M, Antoniadi M, Xemelidis N, Kona V, Markantionis S. A double-blind, randomised clinical trial of the effect of omega-3 fatty acids on the oxidative stress of preterm neonates fed through parenteral nutrition. Eur J Clin Nutr. 2010;64:940–7.
17. Sadzak A, Mravljak J, Maltar-Strmečki N, Arsov Z, Baranović G, Erceg I, Krichbaum M, Strasser V, Přibyl J, Segota S. The structural integrity of the model lipid membrane during induced lipid peroxidation: the role of flavonoids in the inhibition of lipid peroxidation. Antioxidants (Basel). 2020;9(5):430.
18. Beharry KD, Cai CL, Henry MM, Chowdhury S, Valencia GB, Aranda JV. Co-Enzyme Q10 and n-3 polysaturated fatty acid supplementation reverses intermittent hypoxia-induced growth restriction and improved antioxidant profiles in neonatal rats. Frontiers in Neonatology. 2017;6(4):103.
19. Beharry KD, Cai CL, Skelton J, Siddiqui F, D’Agrosa C, Calo J, Valencia GB, Aranda JV. Oxygen-induced retinopathy from recurrent intermittent hypoxia is not dependent on resolution with room air or oxygen, in neonatal rats. Int J Mol Sci. 2018;19(5):E1337.
20. Beharry K, Cai C, Siddiqui F, Chowdhury S, D’Agrosa C, Zangaladze A, Mustafa G, Qadri A, Duggan TJ, Aranda JV. Combination antioxidant/NSAID therapies and oral/topical ocular delivery modes for prevention of oxygen-induced retinopathy in a rat model. Nutrients. 2020;12:1980.
21. Buri PH. The postnatal growth of the rat lung. 3. Morphology. Anat Rec. 1974;180(1):77–98.
22. Tschanz SA, Salim LA, Roth-Kleiner M, Bärre SF, Buri PH, Schiff M, JC. Rat lungs show a biphasic formation of new alveoli during postnatal development. J Appl Physiol. 2014;117(1):99. 
23. Bailey SA, Zidell RH, Perry RW. Relationships between organ weight and body/brain weight in the rat: what is the best analytical endpoint? Toxicol Pathol. 2004;32:484–66.
24. Duggan TJ, Cai CL, Aranda JV, Beharry KD. Acute and chronic effects of intravital bevacizumab on lung biomarkers of angiogenesis in the rat exposed to neonatal intermittent hypoxia. Exp Lung Res. 2020;1–15.
26. Starke PE, Farber JL. Ferric iron and superoxide ions are required for the killing of cultured hepatocytes by hydrogen peroxide: Evidence for the participation of hydroxyl radicals formed by an iron-catalyzed Haber-Weiss reaction. J Biol Chem. 1985;260(18):10099–104.

27. Esterbauer H, Eckl P, Ottner A. Possible mutagens derived from lipids and lipid precursors. Mutat Res. 1990;238(3):223–33.

28. Long EK, Murphy TC, Leiphon LJ, Watt J, Morrow JD, Milne GL, Howard JR, Picklo MJ Sr. Trans-4-hydroxy-2-hexenal is a neurotoxic product of docosahexaenoic (22:6, n-3) acid oxidation. J Neurochem. 2008;105(3):14–24.

29. Leger T, Hinninger-Favier I, Capel F, Geloen A, Rigaudère JP, Jouve C, Pitois E, Pineau G, Vaysse C, Chardigny JM, Michalski MC, Malpuech-Brugère C, Demaison L. Dietary canolol protects the heart against the deleterious effects induced by the association of rapeseed oil, vitamin E and coenzyme Q10 in the context of a high-fat diet. Nutr Metab (Lond). 2018;15:15.

30. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Ischemia-Reperfusion. Compr Physiol. 2016;7(1):113–70.

31. Awada M, Souliage CO, Meynier A, et al. Dietary oxidized n-3 PUFA induce oxidative stress and inflammation: role of intestinal absorption of 4-HHE and reactivity in intestinal cells. J Lipid Res. 2012;53(10):2069–80.

32. Collins CT, Makrides M, McPhee AJ, Sullivan TR, Davis PG, Thio M, Simmer K, Rajadurai VS, Travadi J, Berry MJ, Liley HG, Opie GF, Tan K, Liu K, Morris SA, Stack J, Stark MJ, Chua MC, Jayagobi PA, Holberton J, Bolisetty S, Callander IR, Harris DL, Gibson RA. Docosahexaenoic acid and bronchopulmonary dysplasia in preterm infants. N Engl J Med. 2017;376(13):1245–55.

33. Wang Q, Zhou B, Cui Q, Chen C. Omega-3 long-chain polyunsaturated fatty acids for bronchopulmonary dysplasia: a meta-analysis. Pediatrics. 2019;144(1):20190181.

34. Davis JM, Auten RL. Maturation of the antioxidant system and the effects on preterm birth. Semin Fetal Neonatal Med. 2010;15(4):191–5.

35. Carlsson LM, Jonsson J, Edlund T, Marklund SL. Mice lacking extracellular superoxide dismutase are more sensitive to hyperoxia. Proc Natl Acad Sci USA. 1995;92(14):6264–8.

36. Folz RJ, Abushammas AM, Sulman HB. Extracellular superoxide dismutase in the airways of transgenic mice reduces inflammation and attenuates lung toxicity following hyperoxia. J Clin Invest. 1999;103(7):1055–66.

37. Oury TD, Schaefer LM, Fattman CL, Choi A, Weck KE, Watkins SC. Depletion of pulmonary EC-SOD after exposure to hyperoxia. Am J Physiol Lung Cell Mol Physiol. 2002;283(4):L777–84.

38. Northway WH Jr. Observations on bronchopulmonary dysplasia. J Pediatr. 1979;95:815–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.